Avoid common mistakes on your manuscript.
The year 2022 marked a period of further growth and progress at LUNG. Positive results achieved by a new editorial team in its first two years of stewardship of the journal [1] continued in 2022, as evidenced by numbers of article downloads and an impressive increase of 46% in journal impact factor. High-quality submissions continued to stream in from authors worldwide, resulting in a declining article acceptance rate to under 15%.
Studies of obstructive airway disease comprised a significant portion of articles published is 2022. Clinical studies of COPD examined diagnosis [2], risk factors [3], predictors of outcomes [4,5,6,7,8,9], and therapeutic interventions [10, 11], whereas preclinical investigations evaluated chronic cigarette smoke-induced inflammation and airway remodeling [12, 13]. Contributions in the field of asthma included physiological studies [14,15,16,17,18], effects of therapeutic interventions [19], social determinants of clinical outcomes [20], asthma-associated cough [21, 22] and preclinical investigations [23].
The journal was delighted to feature a number of investigations in the rapidly growing field of Interventional Pulmonology. Published studies evaluated transbronchial lung cryobiopsy [24, 25], endobronchial ultrasound (EBUS)-guided procedures [26,27,28] as well as novel robotic-assisted bronchoscopy and cryobiopsy [29, 30].
Lung cancer remains a major focus of investigation within the fields of pulmonary medicine and oncology. Relevant articles published in LUNG in 2022 reported on diagnostic markers [31], risk factors and prognosis [32,33,34,35,36,37,38], as well as medical [39] and surgical intervention [40].
Appropriate to their significance in pulmonary medicine, interstitial lung diseases (ILD) and idiopathic pulmonary fibrosis (IPF) were well represented in the journal. Studies of IPF investigated potential mechanisms [41], animal models of induced fibrosis [42], potential biomarkers [43] and clinical outcomes [44]. Contributions on the subject of ILD included evaluation of potential biomarkers [45], diagnostic cryobiopsy [24], pediatric ILD [46], ILD outcomes [47], as well as investigations of hypersensitivity pneumonitis [48] and bronchiectasis [49, 50].
In recent years, the study of cough has been among the most active areas of inquiry within pulmonary medicine. Indeed, 2022 witnessed the approval of the first-ever drug indicated for the treatment of refractory chronic cough [51, 52]. LUNG continued its emphasis on high-quality cough-related research by featuring numerous articles, including those examining asthma-associated cough [21, 22]; cough associated with IPF [53] and COVID19 [54]; methodology of objective cough counting [55, 56]; cough-related healthcare utilization [57, 58]; physiology [59]; and, studies of potential antitussive drugs [60,61,62].
Among the goals of the journal in 2022 was to enhance content in preclinical and translational research. To that end, LUNG assigned a Deputy Editor for Basic Science Research to spearhead this effort going forward. Publications during the year included studies relevant to cigarette smoke-induced airway injury and COPD [12, 13]; asthma [23]; pulmonary fibrosis [42]; pulmonary hypertension [63]; sarcoidosis [64]; allergic airway inflammation [65]; immunity [66]; and, acute lung injury [67].
We remain eager to increase publication of high-quality manuscripts in the fields of Critical Care and Pediatric Pulmonology, and invite prospective authors to submit their work for consideration. Studies examining issues in critical illness included intravascular volume management in acute pulmonary embolism [68]; liver transplantation [69]; non-invasive ventilation [70, 71]; pulmonary effects of anesthesia [72]; and, a preclinical examination of acute lung injury [67]. Investigations of pediatric populations included topics such as management of bronchopulmonary dysplasia [73], interstitial lung disease [46] and asthma [17].
Pulmonary arterial hypertension continues to be an active focus of investigation within respiratory medicine. Studies published in 2022 included a State-of-the-Art review on chronic thromboembolic pulmonary hypertension [74]; diagnosis and associated conditions [75, 76]; and, preclinical mechanistic investigations [63]. Contributions in the field of thoracic imaging evaluated diagnostic capabilities of new technological advances in computed tomography [30, 77,78,79,80] as well as prone imaging in chest radiography [81].
The journal remained very selective in accepting COVID-19 related submissions, publishing only two particularly significant articles comparing virulence among SARS-CoV-2 variants [82] and evaluating pandemic-associated cough [54]. Other notable publications in the area of infectious disease included a State-of-the-Art review of Strongyloides stercoralis [83], an outcome analysis of Blastomycosis infections [84], and an investigation of cytomegalovirus (CMV) infection in lung transplant recipients [85].
Additional clinically relevant topics covered in our pages in 2022 included cytokines in lung transplantation [86]; pulmonary function in various populations [87, 88]; effects of tobacco and nicotine use [89, 90]; idiopathic pulmonary hemosiderosis [91]; pulmonary capillary hemangiomatosis [92]; and evaluation of pleural effusions [93].
The editorial team at LUNG steadfastly maintains its goal of continued improvement of the quality and impact of our journal, and to further expand our readership. To that end, we will remain dependent on our colleagues worldwide, working at the bedside and in the laboratory, to contribute their quality work to LUNG.
References
Dicpinigaitis PV (2022) LUNG year in review: 2021. Lung 200(1):1–4
O’Driscoll JM et al (2022) Undiagnosed chronic obstructive pulmonary disease is highly prevalent in patients referred for dobutamine stress echocardiography with shortness of breath. Lung 200(1):41–48
Rahman HH, Niemann D, Munson-McGee SH (2022) Urinary metals, arsenic, and polycyclic aromatic hydrocarbon exposure and risk of self-reported emphysema in the US adult population. Lung 200(2):237–249
Cao P et al (2022) Serum 8-hydroxy-2’-deoxyguanosine predicts severity and prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease. Lung 200(1):31–39
Chen Z et al (2022) Serum creatinine/cystatin C ratio as a predictor of in-hospital mortality in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Lung 200(5):609–617
Golpe R et al (2022) Trajectories of severe exacerbations of chronic obstructive pulmonary disease and their relationship with mortality risk. Lung 200(5):601–607
Ben Anes A et al (2022) Plasma lipid profiling identifies phosphatidylcholine 34:3 and triglyceride 52:3 as potential markers associated with disease severity and oxidative status in chronic obstructive pulmonary disease. Lung 200(4):495–503
Kendra M et al (2022) Decreasing hospital readmissions utilizing an evidence-based COPD care bundle. Lung 200(4):481–486
De Nuccio F, Piscitelli P, Toraldo DM (2022) Gut-lung microbiota interactions in chronic obstructive pulmonary disease (COPD): potential mechanisms driving progression to COPD and epidemiological data. Lung 200(6):773–781
Pini L et al (2022) Acute effect of bronchodilator on intrathoracic airway wall compliance in COPD patients. Lung 200(4):473–480
Sillen MJH et al (2022) Effects of pulmonary rehabilitation including inspiratory muscle training in patients with chronic obstructive pulmonary disease after stratification by the degree of static hyperinflation. Lung 200(4):487–494
Mei X et al (2022) Poly I: C exacerbates airway inflammation and remodeling in cigarette smoke-exposed mice. Lung 200(6):677–686
Garantziotis S (2022) Adding (viral) insult to (smoke) injury may prolong COPD changes after smoking cessation (editorial). Lung 200(6):671–672
Rizzo JA et al (2022) Ventilation rates achieved in eucapnic voluntary hyperpnea challenge and exercise-induced bronchoconstriction diagnosis in young patients with asthma. Lung 200(2):229–236
Chan R, Lipworth B (2022) Forced vital capacity and low frequency reactance area measurements are associated with asthma control and exacerbations. Lung 200(3):301–303
Fang XM et al (2022) Endogenous adenosine 5’-monophosphate, but not acetylcholine or histamine, is associated with asthma control, quality of life, and exacerbations. Lung 200(5):579–589
Chanachon PN et al (2022) Association of dyslipidemia and respiratory resistance assessed by the forced oscillation technique in asthmatic children. Lung 200(1):73–82
Pham DD et al (2022) Different impacts of blood and sputum eosinophil counts on lung function and clinical outcomes in asthma: findings from the COREA cohort. Lung 200(6):697–706
Chan R, Lipworth BJ (2022) Impact of biologic therapy on the small airways asthma phenotype. Lung 200(6):691–696
Alachraf K et al (2022) Social determinants of emergency department visits in mild compared to moderate and severe asthma. Lung 200(2):221–226
Holmes J, Heaney LG, McGarvey LPA (2022) Objective and subjective measurement of cough in asthma: a systematic review of the literature. Lung 200(2):169–178
Diab N et al (2022) Narrative review of the mechanisms and treatment of cough in asthma, cough variant asthma, and non-asthmatic eosinophilic bronchitis. Lung 200(6):707–717
Chiba Y et al (2022) Hyperresponsiveness to extracellular acidification-mediated contraction in isolated bronchial smooth muscles of murine experimental asthma. Lung 200(5):591–599
Castellani C, Castellani H, Benn BS (2022) Transbronchial lung cryobiopsy is safe and effective for diagnosing acutely ill hospitalized patients with new diffuse parenchymal lung disease. Lung 200(2):153–159
Low S-W, Maldonado F (2022) Cryobiopsies for diffuse parenchymal lung disease in acutely ill patients: just because we can does not mean we should (editorial). Lung 200(2):149–151
Walscher J et al (2022) Comparison of a 22G crown-cut needle with a conventional 22G needle with EBUS guidance in diagnosis of sarcoidosis. Lung 200(5):633–641
Torii A et al (2022) EUS-B-FNA enhances the diagnostic yield of EBUS bronchoscope for intrathoracic lesions. Lung 200(5):643–648
Martin-Deleon R et al (2022) EBUS-TBNA in extrathoracic malignancies: diagnostic and prognostic implications. Lung 200(6):747–753
Oberg CL et al (2022) Novel robotic-assisted cryobiopsy for peripheral pulmonary lesions. Lung 200(6):737–745
Styrvoky K et al (2022) Shape-sensing robotic-assisted bronchoscopy with concurrent use of radial endobronchial ultrasound and cone beam computed tomography in the evaluation of pulmonary lesions. Lung 200(6):755–761
Nakashima K et al (2022) Sulfated glycans recognized by S1 monoclonal antibody can serve as a diagnostic marker for malignant pleural mesothelioma. Lung 200(3):339–346
Zhang GH, Liu YJ, Ji MD (2022) Risk factors, prognosis, and a new nomogram for predicting cnacer-specific survival among lung cancer patinets with brain metastasis: a retrospective study based on SEER. Lung 200(1):83–93
Wang T, Zhu X, Wang K (2022) CircMIIP contributes to non-small cell lung cancer progression by binding miR-766-5p to upregulate FAM83A expression. Lung 200(1):107–117
Detopoulou P, Voulgaridou G, Papadopoulou S (2022) Cancer, phase angle and sarcopenia: the role of diet in connection with lung cancer prognosis. Lung 200(3):347–379
Feng Y et al (2022) Genomic analysis reveals the prognostic and immunotherapeutic response characteristics of ferroptosis in lung squamous cell carcinoma. Lung 200(3):381–392
Lococo F et al (2022) Role of peripheral blood markers for detecting response and predicting prognosis in patients with non-small-cell lung cancer undergoing neoadjuvant therapy and surgery. Lung 200(3):393–400
Bertoglio P et al (2022) Impact of high-grade patterns in early-stage lung adenocarcinoma: a multicentric analysis. Lung 200(5):649–660
Shen F et al (2022) Prognostic value of geriatric nutritional risk index for patients with non-small cell lung cancer: a systematic review and meta-analysis. Lung 200(5):661–669
Avrillon V et al (2022) Nationwide real-life safety and treatment exposure data on durvalumab after concurrent chemoradiotherapy in unresectable stage III, locally advanced, non-small cell lung cancer: analysis of patients enrolled in the French Early Access Program. Lung 200(1):95–105
Doerr F et al (2022) Stage I and II small-cell lung cancer-new challenge for surgery. Lung 200(4):505–512
Zhu W, Tan C, Zhang J (2022) Alveolar epithelial type 2 cell dysfunction in idiopathic pulmonary fibrosis. Lung 200(5):539–547
Shao M et al (2022) Pathophysiological changes in rhesus monkeys with paraquat-induced pulmonary fibrosis. Lung 200(5):549–560
Todd JL et al (2022) Association of circulating proteins with death or lung transplant in patients with idiopathic pulmonary fibrosis in the IPF-PRO registry cohort. Lung 200(1):11–18
Kim HJ et al (2022) Clinical outcomes of patients with combined idiopathic pulmonary fibrosis and emphysema in the IPF-PRO registry. Lung 200(1):21–29
Yang S et al (2022) Serum oncomarkers in patients with MPO-ANCA-positive vasculitis: diagnostic and prognostic predictive values for interstitial lung disease. Lung 200(3):331–338
Park H et al (2022) Child interstitial lung disease in an infant with surfactant protein C dysfunction due to c. 202G>T variant (p. V68F). Lung 200(1):67–71
RoyChoudhury A et al (2022) Survival by lung-transplantation preference in interstitial lung disease patients with severe pulmonary hypertension and high lung allocation score (correspondence). Lung 200(1):137–139
Kalra SS et al (2022) Hypersensitivity pneumonitis with and without autoimmune features: a clinical comparative analysis. Lung 200(6):763–771
Lim HF et al (2022) Shortened telomere length in sputum cells of bronchiectasis patients is associated with dysfunctional inflammatory pathways. Lung 200(3):401–407
Araujo AS et al (2022) Effects of pulmonary rehabilitation on systemic inflammation and exercise capacity in bronchiectasis: a randomized controlled trial. Lung 200(3):409–417
McGarvey LP, Birring SS, Morice AH et al (2022) Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 399(10328):909–923. https://doi.org/10.1016/S0140-6736(21)02348-5
Dicpinigaitis PV (2021) Coming soon: the first-ever drug(s) for refractory chronic cough (editorial). Lung 199(2):83–84
Chung KF et al (2022) Tackling the neuropathic cough of idiopathic pulmonary fibrosis (IPF): more needs to be done. Lung 200(6):673–675
Kaulamo JT, Latti AM, Koskela HO (2022) Cough in the elderly during the COVID-19 pandemic. Lung 200(2):161–168
Rudd M, Song W-J, Small PM (2022) The statistics of counting coughs: easy as 1,2,3? (editorial). Lung 200(5):531–537
Schelfhout J et al (2022) Validation and meaningful change thresholds for an objective cough frequency measurement in chronic cough. Lung 200(6):717–724
An J et al (2022) Cough presentation and cough-related healthcare utilization in tertiary care: analysis of routinely collected academic institutional database. Lung 200(4):431–439
Song W-J, Yu C-J, Kang SH (2022) Cough characteristics and healthcare journeys of chronic cough patients in community-based populations in South Korea and Taiwan. Lung 200(6):725–736
Kaneko H, Suzuki A, Horie J (2022) Effects of cough training and inspiratory muscle training on cough strength in older adults: a randomized controlled trial. Lung 200(1):49–57
Nussbaum J et al (2022) A randomized, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of 3 weeks of orally administered gefapixant in healthy younger and older adults. Lung 200(3):315–323
Smith JA et al (2022) Improvements in objective and subjective measures of chronic cough with gefapixant: a pooled phase 3 efficacy analysis of predefined subgroups. Lung 200(4):423–429
McGarvey L, Smith JA, Morice A et al (2022) A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough. Lung. https://doi.org/10.1007/s00408-022-00592-5
Zhai C et al (2022) Activation of autophagy induces monocrotaline-induced pulmonary arterial hypertension by FOXM1-mediated FAK phosphorylation. Lung 200(5):619–631
Shahraki AH et al (2022) Anti-inflammatory properties of the alpha-melanocyte-stimulating hormone in models of granulomatous inflammation. Lung 200(4):463–472
Jaiswal AK, Mishra A (2022) ADAMTS7 attenuates house dust mite-induced airway inflammation and Th2 immune responses. Lung 200(3):305–313
Pausder A et al (2022) Exogenous and endogenous triggers differentially stimulate Pigr expression and antibacterial secretory immunity in the murine respiratory tract. Lung 200(1):119–128
Aydin P et al (2022) Avanafil as a novel therapeutic agent against LPS-induced acute lung injury via increasing CGMP to downregulate the TLR4-NF-ĸB-NLRP3 inflammasone signaling pathway. Lung 200(5):561–572
Ferrari E et al (2022) Diuretics versus volume expansion in the initial management of acute intermediate high-risk pulmonary embolism. Lung 200(2):179–185
Pinto CA et al (2022) ICU and hospital outcomes in patients with hepatopulmonary syndrome undergoing liver transplantation. Lung 200(1):5–10
Shah AJ et al (2022) Factors affecting domiciliary non-invasive ventilation compliance. Lung 200(4):457–462
Franke K-J et al (2022) Non-invasive ventilation: effect of vented and non-vented exhalation systems on inspiratory CO2 and O2 concentrations, ventilation, and breathing pattern. Lung 200(2):251–260
Wilson ML et al (2022) Effects of anesthesia on ozone-induced lung and systemic inflammation. Lung 200(2):269–275
Montoya C et al (2022) Dynamic PEEP study: a non-invasive diagnostic exam to assess for effective PEEP in children with severe BPD. Lung 200(1):59–65
Teerapuncharoen K, Bag R (2022) Chronic thromboembolic pulmonary hypertension. Lung 200(3):283–299
Heresi GA et al (2022) Identifying patinets with group 3 pulmonary hypertension associated with COPD or ILD using an administrative claims database. Lung 200(2):187–203
Murta MS et al (2022) Sleep-disordered breathing in adults with precapillary pulmonary hypertension: prevalence and predictors of nocturnal hypoxemia. Lung 200(4):523–530
Wen X-L et al (2022) Comparison of silicosis and tuberculosis involving mediastinal lymph nodes based on contrast-enhanced multidetector-row computed tomography. Lung 200(2):261–268
Hochhegger B et al (2022) Narrowing the differential diagnosis of cystic lesions in smokers with expiratory CT acquisition using the cyst-airway communication hypothesis. Lung 200(6):817–820
Mandal M, Bhakta P, Esquinas AM (2022) CT scan using a dynamic PEEP protocol to assess optimal PEEP level in infants with bronchopulmonary dysplasia: a few unresolved issues (correspondence). Lung 200(2):277–278
Montoya C et al (2022) Authors’ response: CT sacn using a dynamic PEEP protocol to assess optimal PEEP level in infants with bronchopulmonary dysplasia: a few unresolved issues (correspondence). Lung 200(2):279–281
Lazarus MS et al (2022) Prone chest radiographs: distinguishing features and identification of support devices. Lung 200(4):441–445
Trunfio M et al (2022) Real-life evidence of lower lung virulence in COVID-19 inpatients infected with SARS-CoV-2 Omicron variant compared to wild-type and Delta SARS-CoV-2 pneumonia. Lung 200(5):573–577
Czeresnia JM, Weiss LM (2022) Strongyloides stercoralis. Lung 200(2):141–148
Ahluwalia V et al (2022) Intensive Care Unit and hospital outcomes of patients admitted with Blastomycosis: a 14-year retrospective study. Lung 200(1):129–135
Bennett D et al (2022) Cytomegalovirus infection is associated with development of chronic lung allograft dysfunction. Lung 200(4):513–522
Assadiasl S, Nicknam MH (2022) Cytokines in lung transplantation. Lung 200(6):793–806
Zhang C et al (2022) Abnormal pulmonary function in early Parkinson’s disease: a preliminary prospective observational study. Lung 200(3):325–329
Collaro AJ et al (2022) Association of gas diffusing capacity of the lung for carbon monoxide with cardiovascular morbidity and survival in a disadvantaged clinical population. Lung 200(6):783–792
Lang AE, Yakhkind A, Prom-Wormley E (2022) Tobacco and nicotine use in the United States Army trainee soldier’s environment (correspondence). Lung 200(3):419–421
Wiersma VR et al (2022) The decrease in serum sRAGE levels upon smoking is associated with activated neutrophils. Lung 200(6):687–690
Saha BK et al (2022) Proposed pathogenesis of diffuse alveolar hemorrhage in idiopathic pulmonary hemosiderosis. Lung 200(2):205–215
Kimmig LM et al (2022) Identification of a novel EIF2AK variant and genetics-assisted approach to diagnosis of pulmonary capillary hemangiomatosis. Lung 200(2):217–219
Ak G et al (2022) Evaluation of exudative pleural effusions: a multicenter, prospective, observational study. Lung 200(6):807–815
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Peter Dicpinigaitis, MD, is the Editor-in-Chief of LUNG.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Dicpinigaitis, P.V. LUNG Year in Review: 2022. Lung 201, 1–4 (2023). https://doi.org/10.1007/s00408-022-00594-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-022-00594-3